Hunan Goldliloo Pharmaceutical

Hunan Goldliloo Pharmaceutical is a biopharmaceutical company based in Changsha, China, focused on the development of high-end complex injectable formulations. The company specializes in long-acting microsphere technology, which enables the sustained release of drugs over extended periods to improve patient adherence and therapeutic outcomes. Its pipeline primarily targets chronic conditions within endocrinology, psychiatry, and neurology, with lead candidates for type 2 diabetes and schizophrenia in late-stage clinical development. Goldliloo operates a comprehensive value chain encompassing R&D, clinical trials, and large-scale GMP manufacturing. The company's proprietary platform aims to overcome technical barriers in the production of microspheres, positioning it as a leader in the Chinese complex generics and improved new drug space.